Presynaptic modulation of glutamate release targets different calcium channels in rat cerebrocortical nerve terminals.
We have studied which type/s of Ca2+-channel/s support glutamate exocytosis and its modulation by presynaptic receptors in cerebrocortical nerve terminals. Depolarization of nerve terminals with 30 mM KCl induced a Ca2+-dependent release of 3.64 +/- 0.25 nmol/mg of protein. The addition of either 2 microM omega-conotoxin-GVIA or 200 nM omega-agatoxin-IVA reduced the KCl-evoked release by 47.7 +/- 3.5% and 70.4 +/- 8.9% respectively, and by 85.7 +/- 4.1% when both toxins were co-applied. The activation of adenosine A1 receptors with N6-cyclohexyladenosine or the activation of metabotropic glutamate receptors with L(+)-2-amino-4-phosphonobutyrate inhibited the KCl-evoked release by 41.0 +/- 5.9 and 54.3 +/- 10% respectively. The extent of these inhibitions was not altered by the prior addition of 2 microM omega-conotoxin-GVIA but they were significantly enhanced when omega-agatoxin-IVA was added together with the adenosine A1 receptor agonist or the metabotropic glutamate receptor agonist, suggesting that omega-conotoxin-GVIA-sensitive and not omega-agatoxin-IVA-sensitive Ca2+-channels are involved in the action of these inhibitory receptors. By contrast, the facilitation of glutamate release that follows the activation of the protein kinase C, either with phorbol esters or with the stimulation of phospholipase C-linked metabotropic receptors, was expressed by both omega-conotoxin-GVIA-sensitive and omega-agatoxin-sensitive Ca2+-channels. It is concluded that different Ca2+-channels support the modulation of glutamate release by presynaptic receptors.
Vázquez
E
E
Departamento de Bioquímica, Facultad de Veterinaria, Universidad Complutense, Madrid, Spain.
Sánchez-Prieto
J
J
D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000375:Aging / Q000502:physiology; D000613:Aminobutyrates / Q000494:pharmacology; D000818:Animals; D019256:Cadmium Chloride / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology*; D002540:Cerebral Cortex / Q000254:growth & development / Q000502:physiology*; D004533:Egtazic Acid / Q000494:pharmacology; D005089:Exocytosis; D018698:Glutamic Acid / Q000378:metabolism*; D010455:Peptides / Q000494:pharmacology*; D010703:Phorbol Esters / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects / Q000502:physiology*; D018047:Receptors, Purinergic P1 / Q000187:drug effects / Q000502:physiology; D013111:Spider Venoms / Q000494:pharmacology*; D013574:Synaptosomes / Q000187:drug effects / Q000502:physiology*; D020867:omega-Agatoxin IVA; D020866:omega-Conotoxin GVIA
D000613:Aminobutyrates; D002121:Calcium Channel Blockers; D015220:Calcium Channels; D010455:Peptides; D010703:Phorbol Esters; D018094:Receptors, Metabotropic Glutamate; D018047:Receptors, Purinergic P1; D013111:Spider Venoms; D020867:omega-Agatoxin IVA; C027513:N(6)-cyclohexyladenosine; D018698:Glutamic Acid; D004533:Egtazic Acid; D011189:Potassium Chloride; C028141:4-(phosphonoacetyl)-L-alpha-aminobutyrate; D020866:omega-Conotoxin GVIA; D011493:Protein Kinase C; D019256:Cadmium Chloride; D000241:Adenosine